EXPLORE BAXFENDY / EFFICACY BaxHTN
- A pivotal trial evaluating the effects of BAXFENDY on SBP, published in NEJM
- A pivotal trial demonstrating SBP reductions, day and night, published in The Lancet
In adults with uncontrolled hypertension taking 2 or more antihypertensives,
BAXFENDY 2 mg DELIVERED DOUBLE-DIGIT ABSOLUTE DROPS IN SBP WHEN ADDED TO STANDARD OF CARE[1b],[2b]
BaxHTN[*] Primary Endpoint: Change in Seated SBP With BAXFENDY 2 mg From Baseline to Week 12[1c],[2c]
*^ BaxHTN was a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the effect of BAXFENDY 1 mg and 2 mg plus SOC compared with placebo plus SOC, in patients with a seated SBP ≥140 mm Hg and <170 mm Hg despite the receipt of stable treatment with ≥2 antihypertensive medications. The primary endpoint was the change in seated SBP from Baseline to Week 12. This primary endpoint was analyzed in the modified intention-to-treat population using an analysis of covariance (ANCOVA) model that included treatment and baseline hypertension status (uncontrolled or resistant) as factors, and the baseline seated SBP as a covariate.[1f],[2f]
In adults with uncontrolled hypertension taking 2 or more antihypertensives,
BAXFENDY 1 mg DELIVERED DOUBLE-DIGIT ABSOLUTE DROPS IN SBP WHEN ADDED TO STANDARD OF CARE[1g],[2g]
BaxHTN[*] Primary Endpoint: Change in Seated SBP With BAXFENDY 1 mg From Baseline to Week 12[1h],[2h]
*^ BaxHTN was a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the effect of BAXFENDY 1 mg and 2 mg plus SOC compared with placebo plus SOC, in patients with a seated SBP ≥140 mm Hg and <170 mm Hg despite the receipt of stable treatment with ≥2 antihypertensive medications. The primary endpoint was the change in seated SBP from Baseline to Week 12. This primary endpoint was analyzed in the modified intention-to-treat population using an analysis of covariance (ANCOVA) model that included treatment and baseline hypertension status (uncontrolled or resistant) as factors, and the baseline seated SBP as a covariate.[1f],[2f]
-
slide1
-
slide2
†Patients were on maximum tolerated doses based on investigator judgment for ≥4 weeks prior to screening.
‡Including a diuretic.
§Other inclusion criteria: ≥18 years of age, eGFR ≥45 mL/min/1.73 m2, serum K+ ≥3.5 & <5.0 mmol/L.
||Data are mean (standard deviation).
With BAXFENDY By Your Side, prescribe with confidence
FIND SUPPORT RESOURCESAbbreviations: ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; BB=beta blocker; CCB=calcium channel blocker; CI=confidence interval; eGFR=estimated glomerular filtration rate; FDA=Food and Drug Administration; K+=potassium; NEJM=The New England Journal of Medicine; QD=once daily; SBP=systolic blood pressure; SOC=standard of care.
References:
- 1a 1b 1c 1d 1e 1f 1g 1h 1i 1j 1k BAXFENDY® (baxdrostat) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
- 2a 2b 2c 2d 2e 2f 2g 2h 2i 2j 2k Flack JM, Azizi M, Brown JM, et al; BaxHTN Investigators. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension [including online supplement]. N Engl J Med. 2025;393(14):1363-1374.
- ^ Azizi M, Brown JM, Dwyer JP, et al; Bax24 investigators. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial [including online supplement]. Lancet. 2026;407(10532):988-999.
